St. John's Wort Oil
Hypericum perforatum
Evidence Rating
Confidence Level
Traditions
Last Updated
Summary
St. John's Wort oil (Oleum Hyperici, "Red Oil") is a traditional European wound-healing preparation that is well-recognized in the German-speaking world but virtually unknown in Anglophone dermatology. The topical use is approved by Commission E and ESCOP for minor wounds, burns, and skin inflammation. Hyperforin is the primary wound-healing active compound, stimulating keratinocyte differentiation. Clinical evidence is limited but supportive, including a positive RCT for cesarean wound healing. Photosensitivity concerns, while valid for oral/systemic use, appear minimal for topical application at standard concentrations.
Drug Interactions
This herb has significant drug interactions. Do not use if you are taking medications without consulting a healthcare provider first. See detailed interaction information below.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | ✓ Approved |
| ESCOP (European) | ✓ Approved |
| EMA/HMPC (EU) | ✓ Approved |
Metadata
| Field | Value |
|---|---|
| Common Names (English) | St. John’s Wort Oil, Red Oil, Hypericum Oil |
| Common Names (German) | Johanniskrautol, Rotol, Hypericum-Ol |
| Botanical Name | Hypericum perforatum L. |
| Plant Family | Hypericaceae (formerly Clusiaceae/Guttiferae) |
| Parts Used | Flowering tops macerated in oil (Oleum Hyperici); also tincture and ointment |
| Evidence Quality Rating | Moderate — Commission E and ESCOP approval for topical use; limited clinical trials but strong traditional use basis |
Approved Indications
Commission E (Germany)
- Approved for both internal and external use
- External indications: Treatment and post-treatment of sharp and blunt injuries; myalgia; first-degree burns
- The oil preparation (Oleum Hyperici) is specifically included in the monograph
ESCOP (European Scientific Cooperative on Phytotherapy)
- Approved for external use
- Indications: Mild skin inflammations (e.g., sunburn); small wounds; minor burns
EMA/HMPC (European Medicines Agency)
- Traditional Use classification for topical preparations
- Indications: Traditional herbal medicinal product for symptomatic treatment of minor inflammations of the skin and as an aid in healing of minor wounds
- Note: The EMA monograph primarily addresses oral use for depression; topical use receives less detailed assessment
Agreement/Disagreement Between Bodies
- Good agreement on minor wounds and burns (first-degree)
- Commission E is broadest, including myalgia and sharp/blunt injuries
- ESCOP includes sunburn specifically
- EMA provides minimal detail on topical use compared to oral use
- Important: All bodies recognize the topical use as distinct from oral antidepressant use
Conditions Treated
Primary (Monograph-Supported)
- First-degree burns (including sunburn / dermatitis solaris)
- Minor wounds (sharp and blunt injuries)
- Mild skin inflammations
- Myalgia (Commission E)
Secondary (Clinical/Traditional Use)
- Pressure sores (case reports)
- Cesarean wound healing (RCT evidence)
- Atopic dermatitis (hyperforin-rich preparations)
- Abrasions and contusions
- Bruises
- Ulcers (traditional)
- Neonatal skin care (traditional use in some Mediterranean cultures)
Mechanism of Action
Key Active Compounds
- Hyperforin (phloroglucinol derivative) — primary wound-healing compound; stimulates keratinocyte growth and differentiation; potent antimicrobial
- Hypericin (naphthodianthrone) — photosensitizer; anti-inflammatory; antimicrobial; gives the oil its characteristic red color
- Pseudohypericin — related naphthodianthrone
- Flavonoids (hyperoside, rutin, quercetin) — antioxidant, anti-inflammatory
- Tannins — astringent
- Essential oil — antimicrobial
Mechanisms
- Keratinocyte stimulation: Hyperforin stimulates growth and differentiation of keratinocytes, directly promoting re-epithelialization [Source: PMID 10809859]
- Anti-inflammatory: Hyperforin inhibits COX-1, 5-LOX, and allostimulatory capacity of epidermal cells; reduces inflammatory cytokine release
- Antimicrobial: Hyperforin has potent activity against Gram-positive bacteria including MRSA; hypericin has antiviral properties
- Antioxidant: Flavonoid-mediated free radical scavenging
- Immunomodulatory: Topical hyperforin inhibits the allostimulatory capacity of epidermal cells (relevant to atopic dermatitis) [Source: PMID 10809859]
Preparation of Oleum Hyperici
The traditional preparation involves macerating fresh flowering tops in olive or sunflower oil and exposing the mixture to sunlight for 2-6 weeks. During this period, the oil turns blood-red (from hypericin extraction) and the preparation is then filtered and ready for use. This maceration method is critical to the pharmacological profile — it extracts lipophilic compounds differently than hydroalcoholic tinctures.
Clinical Evidence Summary
Key Clinical Trials
| Study | Design | N | Condition | Result |
|---|---|---|---|---|
| Samadi et al. (2010) | RCT, double-blind | 144 | Cesarean wound healing | Hypericum cream significantly improved wound healing, reduced scar formation, pain, and pruritus (p < 0.05) |
| Schempp et al. (2003) | RCT, half-side comparison | 21 | Atopic dermatitis | Hyperforin-rich cream (1.5% hyperforin) significantly superior to vehicle for eczema severity (p < 0.05) |
| Schempp et al. (2000) | Controlled study | 12 | Photosensitivity assessment | No clinically significant phototoxicity from topical application |
Case Reports
- Yildirim et al. (2016): Pressure sore treatment with H. perforatum oily extract — positive wound healing outcomes in case report [Source: J Ethnopharmacol]
Evidence Assessment
- Cesarean wound healing: One well-designed RCT showing significant benefit
- Atopic dermatitis: One positive small RCT using hyperforin-rich preparation
- Burns/sunburn: Primarily traditional use evidence; no high-quality RCTs identified [NEEDS-RESEARCH]
- General wound healing: Strong pharmacological rationale but limited clinical trials
- Overall: Clinical research is still scarce despite strong traditional use and pharmacological evidence. More RCTs are needed, particularly for the burns indication that is the primary traditional use. [NEEDS-RESEARCH]
European vs US/Anglophone Consensus
| Aspect | European Position | US/Anglophone Position |
|---|---|---|
| Regulatory status | Commission E and ESCOP approved for topical use | Not recognized; no FDA monograph for topical use |
| Clinical awareness | Widely known topical wound/burn remedy, especially in German-speaking countries | Virtually unknown — St. John’s Wort is associated exclusively with oral antidepressant use |
| Product availability | Oleum Hyperici widely available in pharmacies | Rarely available; not stocked in typical pharmacies |
| Clinical use | Part of standard phytotherapy wound care toolkit | Not used in conventional dermatology |
| Research focus | Balanced attention to both oral and topical uses | Overwhelming focus on oral antidepressant use; topical research neglected |
This is perhaps the single largest gap in US/Anglophone awareness among all herbs in this knowledge base. The topical wound-healing use of St. John’s Wort oil is a well-established component of European folk and professional medicine that has essentially zero penetration into English-speaking dermatological practice.
Safety Profile
Contraindications
- Known hypersensitivity to Hypericum perforatum
- Not recommended on heavily irradiated skin or immediately before intense sun exposure (precautionary)
Drug Interactions (Topical Use)
- Topical: No significant drug interactions reported (the extensive drug interaction profile of oral St. John’s Wort does NOT apply to topical use)
- The CYP3A4 induction and serotonin syndrome risks are specific to oral/systemic administration
Side Effects
- Photosensitivity: The most commonly raised concern. However, clinical evidence (Schempp et al. 2000) shows no severe phototoxic potential from topical application at standard concentrations. A trend toward increased sensitivity was detected with sensitive photometric measurement, potentially relevant in fair-skinned individuals, diseased skin, or with extended sun exposure [Source: PMID 10885442]
- Rare: Contact dermatitis (uncommon)
- Generally well tolerated topically
Pregnancy/Lactation
- Topical use: No specific contraindication established; generally considered safe
- Oral use: Controversial during pregnancy/lactation (but this is not relevant to topical wound care)
Clinical Dosage
Topical Preparations
| Form | Dosage/Concentration | Notes |
|---|---|---|
| Oleum Hyperici (macerated oil) | Hypericin ~110 microg/mL | Traditional preparation; apply directly or as dressing |
| Ointment | Hypericin ~30 microg/mL | For skin inflammation |
| Hyperforin-rich cream | 1.5% hyperforin | Used in atopic dermatitis trial |
| Tincture (topical) | 1:10 in olive oil (traditional) | For wound cleansing |
Key Commercial Products (Europe)
- Oleum Hyperici (various pharmacy preparations)
- Hypericum oil (red oil) — widely available in German/Austrian pharmacies
- Behnke Johanniskrautol
- Various anthroposophic preparations (Wala, Weleda)
Sources
- Commission E Monograph: Hypericum perforatum (includes external use)
- ESCOP Monograph: Hyperici herba
- EMA Assessment: Hypericum perforatum (primarily oral; topical use noted)
- Altmeyers Encyclopedia: Hyperici herba
- Samadi et al. (2010). Hypericum for cesarean wound healing. PMID: 20064022
- Schempp et al. (2003). Hyperforin-rich cream for atopic dermatitis. Phytomedicine.
- Schempp et al. (2000). Topical photosensitivity. PMID: 10885442
- Planta Medica (2013). Topical application of St. John’s wort review. PMID: 24214835